Biotechnology
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.
SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinicalstudies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor...
2022-04-20 08:00
1688
Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer
NEW YORK and HONG KONG, April 20, 2022 /PRNewswire/ -- Treadwell Therapeutics (" Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, announced today the appointment of J.D. Mowery as Chief Operating Officer (COO). Reporting into...
2022-04-20 04:30
1921
Mission Bio Partners with S2 Genomics to Offer Robust Solid Tumor Sample Prep for Single-Cell DNA Analysis
MSKCC lab paired Tapestri and Singulator 100 to demonstrate automated nuclei extraction workflow for fast and reliable nuclei prep for single-cell DNA analysis SOUTH SAN FRANCISCO, Calif., April 19, 2022 /PRNewswire/ -- Mission Bio, Inc. , the pioneer in high-throughput single-cell DNA and multi-...
2022-04-19 20:00
1851
Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan
* Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older inJapan * Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination GAITHERSBURG, Md., April 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi...
2022-04-19 19:15
2656
GILEAD SCIENCES AND NATIONAL FOUNDATION OF DIGESTIVE DISEASES SET OUT TO STRENGTHEN LEARNING, ACCESS TO LIVER HEALTH EDUCATION IN SINGAPORE
-- Gilead Sciences supports National Foundation of Digestive Diseases with grant funding to improve liver health education inSingapore as part of its Asia Pacific ALL4LIVER Grant -- -- The National Foundation of Digestive Diseases gets digital upgrade to enhance liver health awareness and educa...
2022-04-19 11:00
2033
Bridge Biotherapeutics Enters into an Exclusive License Agreement with Shaperon to Strengthen Its IPF Franchise
* The licensing deal includes an upfront payment of USD 1.63 million, and may reach up toUSD 24.4 million in milestone payments and royalties * By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive tre...
2022-04-19 09:19
1803
GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate
SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic an...
2022-04-19 09:00
1562
Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases
* New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress * Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine GAITHERSBURG, Md., April 18, 2022 /PRNewswire/ -- Novavax...
2022-04-18 22:13
3066
A Brainwave Technology from Hyundai Mobis Proven to Reduce Drowsiness and Inattentive Driving by Up to 1/3
* M.Brain, the world's first brainwave technology developed last year, proven to be effective in a pilot application. * Cuts down drowsiness after meals by 30% and on highways by 20% max. Also, reduces time taken to recover attention by three times. * Hyundai Mobis secures competitiveness...
2022-04-18 21:00
2093
Illumina Singapore Jumps the Ranks to Earn Two Significant Spots in Singapore's Best Employers Award
The Annual Singapore's Best Employers survey is sponsored by The Straits Times and marketing firm, Statista. SINGAPORE, April 18, 2022 /PRNewswire/ -- Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) was honoured today to be ranked #17 overall and #1 in Healthcare Equipment & Servic...
2022-04-18 12:00
2929
WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC
SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award for Bioprocessing Excellence in Viral Clearance and Safety at the A...
2022-04-15 09:03
2134
Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy
SHANGHAI, April 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative pharmaceutical company specializing in the treatment of genitourinary cancers and related major diseases, announced its 2021 annual report today. The company is currently making steady progress in mu...
2022-04-14 22:49
2295
DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES
Pre-clinical & clinical exploratory poster presentations to highlight oncology
results with
Debio 0123, xevinapant, and Multilink™ technology for antibody drug conjugates
LAUSANNE, Switzerland, April 14, 2022 /PRNewswire/ -- Debiopharm, (
www.debiopharm.com/debiopharm-international/
2022-04-14 21:20
2660
CDD Vault Integrates with SnapGene Server for Web-Based Sharing of Plasmid Information
BURLINGAME, Calif. and SAN DIEGO, April 14, 2022 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD) announced today that it has completed the integration of SnapGene Server with its flagshipCDD Vault research informatics platform. This integration allows users to visualize and share plasmid...
2022-04-14 20:45
2369
Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting
PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
2022-04-14 20:30
2315
International Team Led by BGI Completes First Whole-Body Cell Atlas of a Non-Human Primate
The research will provide insights into the development of potential treatments for neurological diseases and obesity, among other human conditions. SHENZHEN, China, April 14, 2022 /PRNewswire/ -- In a breakthrough that could lead to scientific advancement in the treatment of human diseases, rese...
2022-04-14 16:43
2337
International Team Led by BGI Completes First Whole-Body Cell Atlas of a Non-Human Primate
The research will provide insights into the development of potential treatments for neurological diseases and obesity, among other human conditions. SHENZHEN, China, April 14, 2022 /PRNewswire/ -- In a breakthrough that could lead to scientific advancement in the treatment of human diseases, rese...
2022-04-14 16:30
1776
Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/LAG-3...
2022-04-14 15:39
1903
Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/CD73 ...
2022-04-14 15:05
1684
Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT...
2022-04-14 14:54
1906
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 273 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
13075
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
9154
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8279
